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Opinion
Over the last few decades, exhaled breath has been keeping 
constant attention of the medical community as it has often been 
reported as one of the most promising low invasiveness matrix for 
potential diagnosis of various diseases [1,2]. Indeed, as the volatile 
organic compounds (VOCs) contained in the exhaled air of a human 
being are linked to metabolic pathways taking place in the body, 
one can expect the VOC fingerprint to be impacted by pathologies, 
especially in the case of pulmonary diseases, but not only as VOCs 
are blood-borne chemicals. It is therefore open season for the hunt of 
exhaled biomarkers in analytical laboratories, and many mavericks 
have been out chasing these days, with various levels of success. 
Looking into the scientific literature, because of the heterogenicity 
in study design, sampling approaches, measurements, and data 
processing, one can barely find comparable studies and conclude 
on any robust (sets of) VOCs for specific disease diagnostic. 
Although existing in other area of biomedical research [3], virtually 
no guidelines or standardization exist in this specific field of breath 
volatolomics [4] and that is the major issue.
In breathomics, properly defining the clinical question is the 
first important step to consider to adequately design a study. Such 
task is to be addressed jointly by both medical and analytical teams, 
whom sometimes have first to adopt a common language. This has 
a direct impact on the analytical procedures to implement but also 
on the possible outcomes and conclusions of a study. The justness 
of this first step is often neglected and is at least partly responsible 
for the limited usability of resulting data sets to answer the original 
question afterwards.
As always in analytical chemistry, the sampling step is crucial. 
The selection of the relevant breath fraction (mixed expiratory 
 
breath, late expiratory breath, alveolar breath…), the type of 
potential collection container (polymer bags, syringes, canisters…), 
and the pre-concentration techniques are to be properly and 
exhaustively documented as breath collection is challenging 
and has significant impact on the composition of the sample [5]. 
Furthermore, complete or sorbent-based selective transfer of 
samples to the measuring device (e.g., Selected-Ion Flow-Tube Mass 
Spectrometer, SIFT-MS; or comprehensive two-dimensional gas 
chromatography time-of-flight high resolution mass spectrometry, 
GC×GC-HRTOFMS) [6,7] introduces various levels of analytical 
biases and sensitivity issues. Such a situation might perfectly be 
fine to isolate putative biomarkers or chemical profiles to build 
diagnostic models but must be clearly acknowledged to ensure 
proper usage of the data.
Next, post-acquisition data analysis itself requires an extra 
level of care to ensure monitoring and control over this often-
overlooked critical step. Implementation of basic important 
criteria such as test set/validation set population sizes and proper 
handling of confounding factors have to be carried out. All details 
of the complete data processing workflows including in-depth 
validation of the statistical models used must be made available. 
It starts from data alignment, pre-processing data transformation 
(i.e., normalization, scaling, log transformation), (un)supervised 
screening, and data reduction using univariate (e.g., Fisher 
Ratio, ANOVA) and multivariate (e.g., PLS-DA, supervised and 
unsupervised random forest) [8]. If pattern-recognition statistical 
techniques, clusterisation, or classification models are brought 
into play to allow possible imaging of specific profiles after data 
reduction, they have to be tested for accuracy and robustness. At 
least receiver operating characteristic (ROC) processes should 
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be implemented to assess the diagnosis ability of any putatively 
identified biomarkers [9]. One has globally to better cultivate our 
ability to ensure data integrity over the entire data processing 
journey to provide valuable analytical insights to the medical 
community and make breathomics move up over the technology 
readiness levels (TRLs).
In any cases, when searching for disease-specific VOCs produced 
by subtle changes in specific biochemical pathways, uniformity is 
mandatory to ensure reproducibility and comparability. Even when 
the required technical expertise is met, QA/QC aspects are rarely 
considered. Calling on reference materials, analytical validation, or 
proficiency testing is not common in breathomics but is needed to 
establish enough robustness in discriminating patient from healthy 
controls for the approach to be utilized at the clinical level. Global 
method performances could more easily be estimated by simply 
using benchmark datasets that would be made available for the 
analytical developers [10]. Categorizing the level of confidence one 
can have over putative biomarkers is also of prime interest and 
solutions for harmonization such as the Metabolomics Standards 
Initiative (MSI) confidence level scaling system are now available 
[11]. This contributes to further facilitate the transposition of 
biomarkers from one study to another, bringing higher level of 
usability of breath analysis in the medical field.
It will only be at the price of stronger and more implemented 
robust analytical strategies that breath volatolomics will have a 
real meaning in medical applications. The potential is significant 
for early diagnosis, for monitoring response to treatment, and for 
precision medicine. At some point, it will be required to shift from 
the usage of highly sophisticated separation science tools to more 
routine-adapted devices, ensuring rapid, reliable and affordable 
screening. Moreover, hybrid approaches that combine VOC profiles 
collected from several samples taken from a same patient [12] 
could even increase the diagnostic value. Combining such multiple 
VOC measurements with existing clinical methods (e.g., Fractional 
exhaled Nitric Oxide FeNO, immunotesting, CT scan, …) might be 
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